ImmunoGen revenue was $132.3 m in FY, 2020 which is a (60.8%) year over year increase from the previous period.
ImmunoGen revenue breakdown by business segment: 51.8% from Non-Cash Royalty Revenue, 48.2% from License and Milestone Fees and 0.0% from Other
|FY, 2019||FY, 2020||FY, 2018|
|Non-Cash Royalty Revenue||$47.42 m||$68.53 m||$32.15 m|
|License and Milestone Fees||$34.79 m||$63.74 m||$15.28 m|
|Clinical Materials Revenue||$4.64 m|
|Research and Development Support||$68 k||$28 k||$1.38 m|
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.